Imugene Limited (AU:IMU) has released an update.
Imugene Limited has presented positive data at the AACR Annual Meeting, showing its oncolytic virotherapy VAXINIA, alone or with KEYTRUDA, safely treats advanced cancer with notable responses in biliary tract cancer. Additionally, their B cell immunotherapy HER-Vaxx offered a 40% overall survival benefit over chemotherapy and is linked to tumor reduction. These findings underscore the potential of Imugene’s therapies to offer new hope for treatment-resistant cancers.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
